NCT07288359 2026-02-23Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNovartisPhase 1/2 Recruiting205 enrolled